In a turbulent market environment, SCLX stock has reached a 52-week low, trading at $0.33, with a market capitalization of $62.12 million. This price level reflects a significant downturn for the ...

The US FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for acute treatment, while Nurtec can be taken for immediate symptom relief.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...